All In Biotech

NDA 022429 · Bionpharma

Cetirizine Hydrochloride Allergy

Cetirizine Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Jan 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jul 23, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

134

35 Phase 3, 7 recruiting

FAERS reports

79,983

60,044 serious, 9,000 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 24, 2026.

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: ■ runny nose ■ sneezing ■ itchy, watery eyes ■ itching of the nose or throat

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 23, 2009 Original approval · Type 3 - New Dosage Form Review
4 products under this application
  • CETIRIZINE HYDROCHLORIDE ALLERGY · CETIRIZINE HYDROCHLORIDE 10MG · CAPSULE, ORAL · Over-the-counter
  • CETIRIZINE HYDROCHLORIDE HIVES RELIEF · CETIRIZINE HYDROCHLORIDE 10MG · CAPSULE, ORAL · Over-the-counter
  • CETIRIZINE HYDROCHLORIDE HIVES RELIEF · CETIRIZINE HYDROCHLORIDE 5MG · CAPSULE, ORAL · Over-the-counter
  • CETIRIZINE HYDROCHLORIDE ALLERGY · CETIRIZINE HYDROCHLORIDE 5MG · CAPSULE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Cetirizine" as an intervention, any sponsor and status, largest first.

All 134 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective13,781
  • fatigue13,767
  • pain12,748
  • rash10,518
  • off label use10,250
  • abdominal discomfort9,800
  • alopecia9,656
  • rheumatoid arthritis9,145
  • systemic lupus erythematosus8,883
  • pemphigus8,676
  • swelling8,337
  • hypersensitivity8,238

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004244
2005246
2006202
2007278
2008491
2009436
2010488
2011772
2012958
2013989
20141,485
20152,185
20163,341
20173,253
20184,187
20195,111
20206,163
20218,587
20228,097
20237,366
20249,149
20259,499
20266,456

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 531 on PubMed

Sponsor: Bionpharma · Also marketed as Cetirizine Hydrochloride Hives Relief

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.